Genzyme, a Sanofi Company
Clinical trials sponsored by Genzyme, a Sanofi Company, explained in plain language.
Biotech subsidiary of Sanofi, focused on rare diseases and multiple sclerosis.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a pill replace infusions for gaucher brain symptoms? Results expected Oct 2026 (estimated)
- New drug shows promise in reducing bleeding for hemophilia patients Results expected Nov 2026 (estimated)
- Pompe disease patients get continued enzyme therapy in Long-Term safety study Results expected Jun 2027 (estimated)
-
Experimental MS drug tested in kids, but study halted early
Disease control Stopped earlyThis study tested the drug alemtuzumab in children aged 10 to 18 with relapsing-remitting multiple sclerosis (MS) whose disease was still active despite other treatments. The goal was to see if the drug could reduce new brain lesions and improve quality of life. However, the tria…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control Stopped earlyThis Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental kidney drug for alport syndrome falls short in early trial
Disease control Stopped earlyThis phase 2 trial tested a weekly injection of lademirsen in 43 adults with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug could slow the decline in kidney function. The study was terminated early, so the results are limited and it's u…
Phase 2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 26, 2026 16:08 UTC